France to Roll Out Nationwide Targeted Lung Cancer Screening by 2030

The French government has announced plans to implement targeted lung cancer screening nationwide by 2030, aiming to improve early detection rates and reduce mortality associated with one of the country's deadliest cancers.

A Major Step Forward in Lung Cancer Prevention

While France continues to grapple with the persistent threat of lung cancer, responsible for roughly 30,400 deaths each year, health authorities are turning the page on traditional approaches. Despite advances in treatment, the disease remains the country’s deadliest malignancy, largely because diagnoses often arrive late—after options have narrowed considerably.

Targeted Screening: The Next Frontier

Now, a fresh strategy is on the horizon. During World Cancer Day, Health Minister Stéphanie Rist revealed a bold initiative set to begin in March 2026: a nationwide pilot project aiming to transform prevention and early detection. Spearheaded by the IMPULSION program, under the direction of AP-HP and the Lyon University Hospitals (Hospices Civils de Lyon), this unprecedented campaign will enroll more than 20,000 participants. The ultimate ambition? By 2030, roll out broad-based screening for at-risk populations—aligned with the roadmap established by the French National Cancer Institute (Inca). Authorities hope such efforts could reduce so-called “preventable” lung cancers by as much as a quarter.

Who Can Participate?

Several factors explain this decision:

• Candidates must be between 50 and 74 years old.
• A history of smoking at least 20 pack-years is required.
• Cessation of smoking must be within the past fifteen years.

That said, certain female candidates with specific prior health conditions will be excluded, according to guidelines from the AP-HP. These eligibility rules are designed to focus resources where evidence suggests they’ll have the most impact.

The Promise of Low-Dose CT Scans

Central to this program is a technological advance: the use of low-dose chest CT scans. This method offers a less invasive and swifter alternative to traditional imaging techniques, exposing patients to reduced levels of X-ray radiation while still catching potential tumors at their earliest stages. International studies increasingly converge on one conclusion—among high-risk groups, such scans could lower mortality by up to 25%.

Currently in France, many diagnoses come either through incidental findings during unrelated scans or after respiratory symptoms like persistent cough or unexplained shortness of breath have already emerged—a point at which treatment can be far less effective. By intervening sooner through targeted screening, public health officials are betting on changing not only survival statistics but also patients’ lived realities.

The stakes could hardly be higher—or more urgent.